{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T11:12:13Z","timestamp":1770635533609,"version":"3.49.0"},"reference-count":110,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Division of Intramural Research (DIR)"},{"name":"National Institute of Allergy and Infectious Diseases (NIAID)"},{"name":"National Institutes of Health (NIH)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>While two Plasmodium falciparum circumsporozoite protein-based pre-erythrocytic vaccines (PEV), RTS,S and R21, have been approved by the WHO, no blood-stage vaccine (BSV) or transmission-blocking vaccine (TBV) has reached a phase 3 trial. One of the major obstacles that slows down malaria vaccine development is the shortage (or lack) of in vitro assays or animal models by which investigators can reasonably select the best vaccine formulation (e.g., antigen, adjuvant, or platform) and\/or immunization strategy (e.g., interval of inoculation or route of immunization) before a human phase 2 trial. In the case of PEV, RTS,S and R21 have set a benchmark, and a new vaccine can be compared with (one of) the approved PEV directly in preclinical or early clinical studies. However, such an approach cannot be utilized for BSV or TBV development at this moment. The focus of this review is in vitro assays or in vivo models that can be used for P. falciparum BSV or TBV development, and I discuss important considerations during assay selection, standardization, qualification, validation, and interpretation of the assay results. Establishment of a robust assay\/model with proper interpretation of the results is the one of key elements to accelerate future vaccine development.<\/jats:p>","DOI":"10.3390\/vaccines12060586","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T05:19:49Z","timestamp":1716873589000},"page":"586","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["How to Accelerate Early Stage of Malaria Vaccine Development by Optimizing Functional Assays"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4455-2432","authenticated-orcid":false,"given":"Kazutoyo","family":"Miura","sequence":"first","affiliation":[{"name":"Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD 20852, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2024, April 22). World Malaria Report 2023. Available online: https:\/\/www.who.int\/teams\/global-malaria-programme\/reports\/world-malaria-report-2023."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1016\/j.vaccine.2023.04.011","article-title":"Modelling the relative cost-effectiveness of the RTS,S\/AS01 malaria vaccine compared to investment in vector control or chemoprophylaxis","volume":"41","author":"Topazian","year":"2023","journal-title":"Vaccine"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1473-3099(23)00816-2","article-title":"The public health impact and cost-effectiveness of the R21\/Matrix-M malaria vaccine: A mathematical modelling study","volume":"24","author":"Schmit","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Miura, K., Flores-Garcia, Y., Long, C., and Zavala, F. (2024). Vaccines and monoclonal antibodies: New tools for malaria control. Clin. Microbiol. Rev.","DOI":"10.1128\/cmr.00071-23"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Takashima, E., Otsuki, H., Morita, M., Ito, D., Nagaoka, H., Yuguchi, T., Hassan, I., and Tsuboi, T. (2024). The need for novel asexual blood-stage malaria vaccine candidates for Plasmodium falciparum. Biomolecules, 14.","DOI":"10.3390\/biom14010100"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/0972-9062.318308","article-title":"An analytical review of vector- and pathogen-based transmission-blocking vaccine for malaria control","volume":"59","author":"Jakhar","year":"2022","journal-title":"J. Vector Borne Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bonam, S.R., Renia, L., Tadepalli, G., Bayry, J., and Kumar, H.M.S. (2021). Plasmodium falciparum malaria vaccines and vaccine adjuvants. Vaccines, 9.","DOI":"10.3390\/vaccines9101072"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41541-020-0196-3","article-title":"Malaria vaccines since 2000: Progress, priorities, products","volume":"5","author":"Duffy","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14760584.2019.1674145","article-title":"Malaria transmission-blocking vaccines: Wheat germ cell-free technology can accelerate vaccine development","volume":"18","author":"Miura","year":"2019","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1080\/14760584.2021.1882309","article-title":"Correlates of malaria vaccine efficacy","volume":"20","author":"Stanisic","year":"2021","journal-title":"Expert Rev. Vaccines"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1586\/14760584.2016.1141680","article-title":"Progress and prospects for blood-stage malaria vaccines","volume":"15","author":"Miura","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.pt.2016.07.003","article-title":"Functional antibodies and protection against blood-stage malaria","volume":"32","author":"Teo","year":"2016","journal-title":"Trends Parasitol."},{"key":"ref_13","unstructured":"World Health Organization (2024, April 22). Correlates of Vaccine-Induced Protection: Methods and Implications. Available online: https:\/\/www.who.int\/publications\/i\/item\/WHO-IVB-13.01."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1016\/j.vaccine.2012.05.049","article-title":"Immune markers and correlates of protection for vaccine induced immune responses","volume":"30","author":"Thakur","year":"2012","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1081107","DOI":"10.3389\/fimmu.2022.1081107","article-title":"Recent updates on correlates of vaccine-induced protection","volume":"13","author":"Plotkin","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S1473-3099(15)00239-X","article-title":"Immunogenicity of the RTS,S\/AS01 malaria vaccine and implications for duration of vaccine efficacy: Secondary analysis of data from a phase 3 randomised controlled trial","volume":"15","author":"White","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1016\/S1473-3099(22)00442-X","article-title":"Efficacy and immunogenicity of R21\/Matrix-M vaccine against clinical malaria after 2 years\u2019 follow-up in children in Burkina Faso: A phase 1\/2b randomised controlled trial","volume":"22","author":"Datoo","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(23)02511-4","article-title":"Safety and efficacy of malaria vaccine candidate R21\/Matrix-M in African children: A multicentre, double-blind, randomised, phase 3 trial","volume":"403","author":"Datoo","year":"2024","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41541-021-00372-x","article-title":"Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection","volume":"6","author":"Seaton","year":"2021","journal-title":"NPJ Vaccines"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1016\/j.vaccine.2020.09.069","article-title":"Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S\/AS01 vaccination","volume":"38","author":"Thompson","year":"2020","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.vaccine.2020.12.055","article-title":"Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine","volume":"39","author":"Chaudhury","year":"2021","journal-title":"Vaccine"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"eabb4757","DOI":"10.1126\/scitranslmed.abb4757","article-title":"Mapping functional humoral correlates of protection against malaria challenge following RTS,S\/AS01 vaccination","volume":"12","author":"Suscovich","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e70393","DOI":"10.7554\/eLife.70393","article-title":"Transcriptional correlates of malaria in RTS,S\/AS01-vaccinated African children: A matched case-control study","volume":"11","author":"Moncunill","year":"2022","journal-title":"eLife"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e158030","DOI":"10.1172\/jci.insight.158030","article-title":"Strong off-target antibody reactivity to malarial antigens induced by RTS,S\/AS01E vaccination is associated with protection","volume":"7","author":"Macia","year":"2022","journal-title":"JCI Insight"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1056\/NEJMoa2203067","article-title":"Low-dose subcutaneous or intravenous monoclonal antibody to prevent malaria","volume":"387","author":"Wu","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJMoa2206966","article-title":"Safety and efficacy of a monoclonal antibody against malaria in Mali","volume":"387","author":"Kayentao","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41541-024-00819-x","article-title":"Establishing RTS,S\/AS01 as a benchmark for comparison to next-generation malaria vaccines in a mouse model","volume":"9","author":"Locke","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1086\/339342","article-title":"A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea","volume":"185","author":"Genton","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine","volume":"365","author":"Thera","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMc1100670","article-title":"Protection against malaria by MSP3 candidate vaccine","volume":"365","author":"Sirima","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Palacpac, N.M., Ntege, E., Yeka, A., Balikagala, B., Suzuki, N., Shirai, H., Yagi, M., Ito, K., Fukushima, W., and Hirota, Y. (2013). Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0064073"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/j.vaccine.2016.07.041","article-title":"A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children","volume":"34","author":"Sirima","year":"2016","journal-title":"Vaccine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.medj.2021.03.014","article-title":"Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccination","volume":"2","author":"Minassian","year":"2021","journal-title":"Med"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/infdis\/jit185","article-title":"The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas","volume":"208","author":"Jepsen","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"899223","DOI":"10.3389\/fimmu.2022.899223","article-title":"GMZ2 vaccine-induced antibody responses, naturally acquired immunity and the incidence of malaria in Burkinabe children","volume":"13","author":"Dassah","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jiw039","article-title":"Demonstration of the blood-stage Plasmodium falciparum controlled human malaria infection model to assess efficacy of the P. falciparum Apical Membrane Antigen 1 vaccine, FMP2.1\/AS01","volume":"213","author":"Payne","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41467-019-09894-4","article-title":"A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates","volume":"10","author":"Douglas","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eadf1782","DOI":"10.1126\/scitranslmed.adf1782","article-title":"Vaccination with Plasmodium vivax Duffy-binding protein inhibits parasite growth during controlled human malaria infection","volume":"15","author":"Hou","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1193079","DOI":"10.3389\/fimmu.2023.1193079","article-title":"Analyses of human vaccine-specific circulating and bone marrow-resident B cell populations reveal benefit of delayed vaccine booster dosing with blood-stage malaria antigens","volume":"14","author":"Barrett","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s41120-021-00050-1","article-title":"Best practices for the development and fit- for-purpose validation of biomarker methods: A conference report","volume":"8","author":"Mathews","year":"2022","journal-title":"AAPS Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/1475-2875-11-384","article-title":"Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum","volume":"11","author":"Clement","year":"2012","journal-title":"Malar. J."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1186\/s12936-020-03181-0","article-title":"Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein","volume":"19","author":"Raghunandan","year":"2020","journal-title":"Malar. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12936-023-04591-6","article-title":"Assessment of precision in growth inhibition assay (GIA) using human anti-PfRH5 antibodies","volume":"22","author":"Miura","year":"2023","journal-title":"Malar. J."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Miura, K., Deng, B., Tullo, G., Diouf, A., Moretz, S.E., Locke, E., Morin, M., Fay, M.P., and Long, C.A. (2013). Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0057909"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.ijpara.2012.09.002","article-title":"Measuring the blockade of malaria transmission\u2014An analysis of the standard membrane feeding assay","volume":"42","author":"Churcher","year":"2012","journal-title":"Int. J. Parasitol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"135","DOI":"10.4269\/ajtmh.1999.60.135","article-title":"Differential effect and interaction of monocytes, hyperimmune sera, and immunoglobulin G on the growth of asexual stage Plasmodium falciparum parasites","volume":"60","author":"Shi","year":"1999","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14081","DOI":"10.1038\/srep14081","article-title":"Standardization of the antibody-dependent respiratory burst assay with human neutrophils and Plasmodium falciparum malaria","volume":"5","author":"Llewellyn","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.vaccine.2016.12.028","article-title":"Comparison of functional assays used in the clinical development of a placental malaria vaccine","volume":"35","author":"Pehrson","year":"2017","journal-title":"Vaccine"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1093\/ilar\/ilv009","article-title":"Large animal models for vaccine development and testing","volume":"56","author":"Gerdts","year":"2015","journal-title":"ILAR J."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Herati, R.S., and Wherry, E.J. (2018). What is the predictive value of animal models for vaccine efficacy in humans? Consideration of strategies to improve the value of animal models. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a031583"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jtbi.2019.01.017","article-title":"Dose finding for new vaccines: The role for immunostimulation\/immunodynamic modelling","volume":"465","author":"Rhodes","year":"2019","journal-title":"J. Theor. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1128\/CVI.00042-09","article-title":"Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay","volume":"16","author":"Miura","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2010.04.036","article-title":"The IC(50) of anti-Pfs25 antibody in membrane-feeding assay varies among species","volume":"28","author":"Cheru","year":"2010","journal-title":"Vaccine"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"732667","DOI":"10.3389\/fimmu.2021.732667","article-title":"Poor CD4+ T cell immunogenicity limits humoral immunity to P. falciparum transmission-blocking candidate Pfs25 in humans","volume":"12","author":"Zaric","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e81629","DOI":"10.7554\/eLife.81629","article-title":"Characterisation of the immune repertoire of a humanised transgenic mouse through immunophenotyping and high-throughput sequencing","volume":"12","author":"Richardson","year":"2023","journal-title":"eLife"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e146221","DOI":"10.1172\/JCI146221","article-title":"Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice","volume":"131","author":"Healy","year":"2021","journal-title":"J. Clin. Investig."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/pmic.201700277","article-title":"Antibody profiling by proteome microarray with multiplex isotype detection reveals overlap between human and Aotus nancymaae controlled malaria infections","volume":"18","author":"Taghavian","year":"2018","journal-title":"Proteomics"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"795463","DOI":"10.3389\/fimmu.2022.795463","article-title":"Deep immune phenotyping and single-cell transcriptomics allow identification of circulating TRM-like cells which correlate with liver-stage immunity and vaccine-induced protection from malaria","volume":"13","author":"Noe","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.1254417","article-title":"Antibodies to PfSEA-1 block parasite egress from RBCs and protect against malaria infection","volume":"344","author":"Raj","year":"2014","journal-title":"Science"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41586-020-2220-1","article-title":"Anti-PfGARP activates programmed cell death of parasites and reduces severe malaria","volume":"582","author":"Raj","year":"2020","journal-title":"Nature"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"634508","DOI":"10.3389\/fimmu.2021.634508","article-title":"Progress and insights toward an effective placental malaria vaccine","volume":"12","author":"Gamain","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"ofv044","DOI":"10.1093\/ofid\/ofv044","article-title":"Antibody-dependent cellular inhibition Is associated with reduced risk against febrile malaria in a longitudinal cohort study involving Ghanaian children","volume":"2","author":"Tiendrebeogo","year":"2015","journal-title":"Open Forum Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1161301","DOI":"10.3389\/fimmu.2023.1161301","article-title":"High opsonic phagocytosis activity and growth inhibition of merozoites are associated with RON4 antibody levels and protect against febrile malaria in Ghanaian children","volume":"14","author":"Kusi","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Garcia-Senosiain, A., Kana, I.H., Singh, S., Das, M.K., Dziegiel, M.H., Hertegonne, S., Adu, B., and Theisen, M. (2021). Neutrophils dominate in opsonic phagocytosis of P. falciparum blood-stage merozoites and protect against febrile malaria. Commun. Biol., 4.","DOI":"10.1038\/s42003-021-02511-5"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/infdis\/jiw617","article-title":"Naturally acquired antibodies target the glutamate-rich protein on intact merozoites and predict protection against febrile malaria","volume":"215","author":"Kana","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Osier, F.H., Feng, G., Boyle, M.J., Langer, C., Zhou, J., Richards, J.S., McCallum, F.J., Reiling, L., Jaworowski, A., and Anders, R.F. (2014). Opsonic phagocytosis of Plasmodium falciparum merozoites: Mechanism in human immunity and a correlate of protection against malaria. BMC Med., 12.","DOI":"10.1186\/1741-7015-12-108"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Mansourou, A., Joos, C., Niass, O., Diouf, B., Tall, A., Perraut, R., Niang, M., and Toure-Balde, A. (2022). Improvement of the antibody-dependent respiratory burst assay for assessing protective immune responses to malaria. Open Biol., 12.","DOI":"10.1098\/rsob.210288"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Joos, C., Marrama, L., Polson, H.E., Corre, S., Diatta, A.M., Diouf, B., Trape, J.F., Tall, A., Longacre, S., and Perraut, R. (2010). Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0009871"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1086\/314780","article-title":"High oxygen radical production is associated with fast parasite clearance in children with Plasmodium falciparum malaria","volume":"179","author":"Greve","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1295543","DOI":"10.3389\/fimmu.2023.1295543","article-title":"Acquisition of complement fixing antibodies targeting Plasmodium falciparum merozoites in infants and their mothers in Uganda","volume":"14","author":"Mortazavi","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/s41467-019-08528-z","article-title":"Targets of complement-fixing antibodies in protective immunity against malaria in children","volume":"10","author":"Reiling","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.immuni.2015.02.012","article-title":"Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria","volume":"42","author":"Boyle","year":"2015","journal-title":"Immunity"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Hassan, I., Kanoi, B.N., Nagaoka, H., Sattabongkot, J., Udomsangpetch, R., Tsuboi, T., and Takashima, E. (2023). High-throughput antibody profiling identifies targets of protective immunity against P. falciparum malaria in Thailand. Biomolecules, 13.","DOI":"10.3390\/biom13081267"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"893","DOI":"10.3389\/fimmu.2020.00893","article-title":"Global repertoire of human antibodies against Plasmodium falciparum RIFINs, SURFINs, and STEVORs in a malaria exposed population","volume":"11","author":"Kanoi","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"8621","DOI":"10.1038\/s41598-019-45092-4","article-title":"Antigenicity and immune correlate assessment of seven Plasmodium falciparum antigens in a longitudinal infant cohort from northern Ghana","volume":"9","author":"Kusi","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jiz088","article-title":"Breadth of functional antibodies is associated with Plasmodium falciparum merozoite phagocytosis and protection sgainst febrile malaria","volume":"220","author":"Kana","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1093\/cid\/cix837","article-title":"Identifying immune correlates of protection against Plasmodium falciparum through a novel approach to account for heterogeneity in malaria exposure","volume":"66","author":"Valmaseda","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Partey, F.D., Castberg, F.C., Sarbah, E.W., Silk, S.E., Awandare, G.A., Draper, S.J., Opoku, N., Kweku, M., Ofori, M.F., and Hviid, L. (2018). Kinetics of antibody responses to PfRH5-complex antigens in Ghanaian children with Plasmodium falciparum malaria. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204452"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"795","DOI":"10.4049\/jimmunol.1300778","article-title":"Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development","volume":"191","author":"Richards","year":"2013","journal-title":"J. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Cutts, J.C., Agius, P.A., Zaw, L., Powell, R., Moore, K., Draper, B., Simpson, J.A., and Fowkes, F.J.I. (2020). Pregnancy-specific malarial immunity and risk of malaria in pregnancy and adverse birth outcomes: A systematic review. BMC Med., 18.","DOI":"10.1186\/s12916-019-1467-6"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Fowkes, F.J., Richards, J.S., Simpson, J.A., and Beeson, J.G. (2010). The relationship between anti-merozoite antibodies and incidence of Plasmodium falciparum malaria: A systematic review and meta-analysis. PLoS Med., 7.","DOI":"10.1371\/journal.pmed.1000218"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"706","DOI":"10.4161\/hv.19712","article-title":"Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?","volume":"8","author":"Duncan","year":"2012","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1084\/jem.186.10.1689","article-title":"Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies","volume":"186","author":"Holder","year":"1997","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"McCarthy, J.S., Marjason, J., Elliott, S., Fahey, P., Bang, G., Malkin, E., Tierney, E., Aked-Hurditch, H., Adda, C., and Cross, N. (2011). A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide(R) ISA 720. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024413"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Druilhe, P., Spertini, F., Soesoe, D., Corradin, G., Mejia, P., Singh, S., Audran, R., Bouzidi, A., Oeuvray, C., and Roussilhon, C. (2005). A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020344"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Yagi, M., Bang, G., Tougan, T., Palacpac, N.M., Arisue, N., Aoshi, T., Matsumoto, Y., Ishii, K.J., Egwang, T.G., and Druilhe, P. (2014). Protective epitopes of the Plasmodium falciparum SERA5 malaria vaccine reside in intrinsically unstructured N-terminal repetitive sequences. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0098460"},{"key":"ref_87","first-page":"466","article-title":"The candidate blood stage malaria vaccine P27A induces a robust humoral response in a fast track to the field phase I trial in exposed and non exposed volunteers","volume":"68","author":"Kamaka","year":"2018","journal-title":"Clin. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41541-020-0160-2","article-title":"Immunization with full-length Plasmodium falciparum merozoite surface protein 1 is safe and elicits functional cytophilic antibodies in a randomized first-in-human trial","volume":"5","author":"Blank","year":"2020","journal-title":"NPJ Vaccines"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S1473-3099(19)30739-X","article-title":"PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: A first-in-human, randomised, double-blind, placebo-controlled study","volume":"20","author":"Sirima","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1093\/cid\/ciy1140","article-title":"First-in-human, randomized, double-blind clinical trial of differentially adjuvanted PAMVAC, a vaccine candidate to prevent pregnancy-associated malaria","volume":"69","author":"Mordmuller","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1038\/s41467-018-05777-2","article-title":"A high throughput screen for next-generation leads targeting malaria parasite transmission","volume":"9","author":"Delves","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Delves, M., Lafuente-Monasterio, M.J., Upton, L., Ruecker, A., Leroy, D., Gamo, F.J., and Sinden, R. (2019). Fueling open innovation for malaria transmission-blocking drugs: Hundreds of molecules targeting early parasite mosquito stages. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02134"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Hill, D.L., Eriksson, E.M., Li Wai Suen, C.S., Chiu, C.Y., Ryg-Cornejo, V., Robinson, L.J., Siba, P.M., Mueller, I., Hansen, D.S., and Schofield, L. (2013). Opsonising antibodies to P. falciparum merozoites associated with immunity to clinical malaria. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0074627"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Ghumra, A., Khunrae, P., Ataide, R., Raza, A., Rogerson, S.J., Higgins, M.K., and Rowe, J.A. (2011). Immunisation with recombinant PfEMP1 domains elicits functional rosette-inhibiting and phagocytosis-inducing antibodies to Plasmodium falciparum. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0016414"},{"key":"ref_95","first-page":"3227","article-title":"Targets of antibodies against Plasmodium falciparum-infected erythrocytes in malaria immunity","volume":"122","author":"Chan","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1002\/jlb.49.6.556","article-title":"The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII","volume":"49","author":"Fleit","year":"1991","journal-title":"J. Leukoc. Biol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1186\/s12936-016-1515-z","article-title":"An inter-laboratory comparison of standard membrane-feeding assays for evaluation of malaria transmission-blocking vaccines","volume":"15","author":"Miura","year":"2016","journal-title":"Malar. J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1186\/s13071-017-2414-z","article-title":"Comparative assessment of An. gambiae and An. stephensi mosquitoes to determine transmission-reducing activity of antibodies against P. falciparum sexual stage antigens","volume":"10","author":"Eldering","year":"2017","journal-title":"Parasit. Vectors"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1365-3024.1994.tb00302.x","article-title":"Plasmodium falciparum malaria transmission-blocking immunity under conditions of low endemicity as in Sri Lanka","volume":"16","author":"Premawansa","year":"1994","journal-title":"Parasite Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ijpara.2006.05.004","article-title":"Reduction and enhancement of Plasmodium falciparum transmission by endemic human sera","volume":"36","author":"Sauerwein","year":"2006","journal-title":"Int. J. Parasitol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.pt.2018.11.003","article-title":"Two-faced immunity? The evidence for antibody enhancement of malaria transmission","volume":"35","author":"Stone","year":"2018","journal-title":"Trends Parasitol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e0037423","DOI":"10.1128\/iai.00374-23","article-title":"Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48\/45","volume":"92","author":"Bansal","year":"2024","journal-title":"Infect. Immun."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1017\/S0031182000076721","article-title":"Heterogeneity in patterns of malarial oocyst infections in the mosquito vector","volume":"106","author":"Medley","year":"1993","journal-title":"Parasitology"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1017\/S0031182004006067","article-title":"Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data","volume":"130","author":"Saul","year":"2005","journal-title":"Parasitology"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"12569","DOI":"10.1038\/s41598-020-69513-x","article-title":"Evaluation and modeling of direct membrane-feeding assay with Plasmodium vivax to support development of transmission blocking vaccines","volume":"10","author":"Miura","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1038\/s41591-022-01721-6","article-title":"Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines","volume":"28","author":"Wei","year":"2022","journal-title":"Nat. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1016\/S2666-5247(21)00266-4","article-title":"WHO International Standard for evaluation of the antibody response to COVID-19 vaccines: Call for urgent action by the scientific community","volume":"3","author":"Knezevic","year":"2021","journal-title":"Lancet Microbe"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/6\/586\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:49:20Z","timestamp":1760107760000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/6\/586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":110,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["vaccines12060586"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12060586","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]}}}